Given the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart failure.

There is a growing recognition of the prevalence and outcomes associated with tricuspid regurgitation, whether in isolation or with concomitant diseases. This program will focus on defining the burden of disease, outlining current guideline directed medical therapy and discussing the recent evidence for transcatheter therapies. Gaps in our current understanding of this complex disease process will also be examined.